share_log

賽生藥業：根據收購守則規則3.8刊發的公告

SCICLONE PHARMA: ANNOUNCEMENT PURSUANT TO RULE 3.8 OF THE TAKEOVERS CODE

Hong Kong Stock Exchange ·  Apr 19 10:50
Summary by Moomoo AI
賽生藥業控股有限公司於2024年4月19日發布公告，提及Silver Pegasus Investment Limited建議以協議安排方式私有化本公司的聯合公告。公告中指出，根據首次公開發售後購股權計劃，已有86,400份購股權失效，而另外60,600份購股權已被行使。此外，公司目前共有628,384,132股已發行股份，以及68,427,132份購股權。公告強調，除已披露信息外，公司無未行使的證券、購股權、衍生工具或可轉換股份的認股權證。董事會對公告內容的準確性承擔責任，並確認經過合理查詢後，公告中無任何遺漏事實。股東及潛在投資者應謹慎行事，並在必要時尋求專業意見。
賽生藥業控股有限公司於2024年4月19日發布公告，提及Silver Pegasus Investment Limited建議以協議安排方式私有化本公司的聯合公告。公告中指出，根據首次公開發售後購股權計劃，已有86,400份購股權失效，而另外60,600份購股權已被行使。此外，公司目前共有628,384,132股已發行股份，以及68,427,132份購股權。公告強調，除已披露信息外，公司無未行使的證券、購股權、衍生工具或可轉換股份的認股權證。董事會對公告內容的準確性承擔責任，並確認經過合理查詢後，公告中無任何遺漏事實。股東及潛在投資者應謹慎行事，並在必要時尋求專業意見。
Sesong Pharmaceutical Holdings Limited issued a notice on 19 April 2024, referring to the joint announcement of Silver Pegasus Investment Limited's proposed privatization by agreement. According to the announcement, 86,400 call options have lapsed under the Initial Public Offering Option Scheme and an additional 60,600 share options have been exercised. IN ADDITION, THE COMPANY CURRENTLY HAS 628,384,132 SHARES ISSUED AND 68,427,132 SHARE OPTIONS. The announcement emphasizes that the Company has no warrants for outstanding securities, call options, derivatives or convertible shares other than disclosed information. The Board assumes responsibility for the accuracy of the contents of the announcement and confirms, after reasonable enquiry, that there are no omissions in the announcement. Shareholders and potential investors should exercise caution and seek professional advice when necessary.
Sesong Pharmaceutical Holdings Limited issued a notice on 19 April 2024, referring to the joint announcement of Silver Pegasus Investment Limited's proposed privatization by agreement. According to the announcement, 86,400 call options have lapsed under the Initial Public Offering Option Scheme and an additional 60,600 share options have been exercised. IN ADDITION, THE COMPANY CURRENTLY HAS 628,384,132 SHARES ISSUED AND 68,427,132 SHARE OPTIONS. The announcement emphasizes that the Company has no warrants for outstanding securities, call options, derivatives or convertible shares other than disclosed information. The Board assumes responsibility for the accuracy of the contents of the announcement and confirms, after reasonable enquiry, that there are no omissions in the announcement. Shareholders and potential investors should exercise caution and seek professional advice when necessary.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more